Conclusively, although HDAC inhibition seems to serve as a promising strategy for bladder cancer therapy, accumulated evidences suggest that for maximizing the anti-tumor effects of HDACis, these may not be used as monotherapy agents, but in combination with other already established drugs and therapeutic schemes, including radiation. Here, HDAC9 is linked to neoplasm.